Understanding Heart Disease and Clotting Risk in a Specific Blood Cell Condition
Atherothrombosis in JAK2V617F clonal hematopoiesis
This research explores how a specific change in blood cells, called JAK2V617F clonal hematopoiesis, leads to a higher risk of heart disease and blood clots.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11116873 on NIH RePORTER |
What this research studies
Many older adults have a condition called clonal hematopoiesis (CH), where certain blood cells have a genetic change. If this change is specifically the JAK2V617F mutation, it significantly raises the chances of heart attacks and dangerous blood clots. Our researchers have seen in lab models that this mutation can speed up the hardening of arteries and increase inflammation. We are using advanced models to pinpoint exactly which types of blood cells and how they interact to cause these serious heart and clotting problems. The goal is to uncover the specific ways this blood cell change contributes to heart disease and clotting, which could lead to new ways to protect patients.
Who could benefit from this research
Good fit: Patients with JAK2V617F clonal hematopoiesis who are at increased risk for atherosclerotic cardiovascular disease and blood clots are the focus of this research.
Not a fit: Patients without the JAK2V617F mutation or those not at risk for atherosclerotic cardiovascular disease may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments or preventive strategies for patients with JAK2V617F clonal hematopoiesis to reduce their risk of heart disease and blood clots.
How similar studies have performed: While the link between clonal hematopoiesis and heart disease is known, this research specifically focuses on the detailed mechanisms of atherothrombosis driven by the JAK2V617F mutation, which has not been extensively investigated.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Wang, Nan — Columbia University Health Sciences
- Study coordinator: Wang, Nan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.